Yesterday, the President & CEO of ChemoCentryx (NASDAQ: CCXI), Thomas Schall, sold shares of CCXI for $363.1K.
See today’s analyst top recommended stocks >>
Based on ChemoCentryx’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $9.55 million and GAAP net loss of $9.42 million. In comparison, last year the company earned revenue of $8.23 million and had a GAAP net loss of $6 million. CCXI’s market cap is $641.9M and the company has a P/E ratio of 45.10. The Company has a Price to Book ratio of 25.1234.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $18.50, reflecting a -29.3% downside. One of the top 25 analysts, according to TipRanks.com, recently recommended Hold CCXI.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
